Pooling the Evidence at the Patient Level: End of the Bivalirudin Saga?

Davide Capodanno; Dominick J. Angiolillo

doi:10.1055/s-0039-3400743

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2020; 120(02): 191-193
DOI: 10.1055/s-0039-3400743

Invited Editorial Focus

Georg Thieme Verlag KG Stuttgart · New York

Pooling the Evidence at the Patient Level: End of the Bivalirudin Saga?

Autoren

Davide Capodanno

¹Division of Cardiology, A.O.U. “Policlinico-Vittorio Emanuele,” University of Catania, Catania, Italy
Dominick J. Angiolillo

²Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States

Abstract

Volltext

Referenzen

References
1 Angiolillo DJ, Rollini F, Franchi F. The quest for the optimal periprocedural antithrombotic treatment strategy in ACS patients undergoing PCI. J Am Coll Cardiol 2018; 71 (11) 1243-1245
2 Capodanno D, Greco A. Risk stratification for bleeding in the elderly with acute coronary syndrome: not so simple. Thromb Haemost 2018; 118 (06) 949-952
3 Biancari F, Brascia D, Onorati F. , et al. Prediction of severe bleeding after coronary surgery: the WILL-BLEED Risk Score. Thromb Haemost 2017; 117 (03) 445-456
4 Singh M. Bleeding avoidance strategies during percutaneous coronary interventions. J Am Coll Cardiol 2015; 65 (20) 2225-2238
5 Neumann F-J, Sousa-Uva M, Ahlsson A. , et al; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40 (02) 87-165
6 Weitz JI, Harenberg J. New developments in anticoagulants: past, present and future. Thromb Haemost 2017; 117 (07) 1283-1288
7 Capodanno D, De Caterina R. Bivalirudin for acute coronary syndromes: premises, promises and doubts. Thromb Haemost 2015; 113 (04) 698-707
8 Perdoncin E, Seth M, Dixon S. , et al. The comparative efficacy of bivalirudin is markedly attenuated by use of radial access: insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Eur Heart J 2016; 37 (24) 1902-1909
9 Angiolillo DJ. Vascular access and antithrombotic therapy in patients with acute coronary syndrome. Lancet 2018; 392 (10150): 801-802
10 Shahzad A, Kemp I, Mars C. , et al; HEAT-PPCI trial investigators. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 2014; 384 (9957): 1849-1858
11 Capodanno D, Gargiulo G, Capranzano P, Mehran R, Tamburino C, Stone GW. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: an updated meta-analysis of 10,350 patients from five randomized clinical trials. Eur Heart J Acute Cardiovasc Care 2016; 5 (03) 253-262
12 Elgendy IY, Capodanno D. Heparin versus bivalirudin for percutaneous coronary intervention: has the debate come to an end?. J Thorac Dis 2017; 9 (11) 4305-4307
13 Cavender MA, Sabatine MS. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Lancet 2014; 384 (9943): 599-606
14 Navarese EP, Schulze V, Andreotti F. , et al. Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome. JACC Cardiovasc Interv 2015; 8 (1 Pt B): 201-213
15 Bikdeli B, McAndrew T, Crowley A. , et al. Individual patient data pooled analysis of randomized trials of bivalirudin versus heparin in acute myocardial infarction: rationale and methodology. Thromb Haemost 2019; 120 (02) 348-361
16 Stone GW, McLaurin BT, Cox DA. , et al; ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355 (21) 2203-2216
17 Kastrati A, Neumann F-J, Schulz S. , et al; ISAR-REACT 4 Trial Investigators. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 2011; 365 (21) 1980-1989
18 Stone GW, Witzenbichler B, Guagliumi G. , et al; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358 (21) 2218-2230
19 Steg PG, van 't Hof A, Hamm CW. , et al; EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013; 369 (23) 2207-2217
20 Han Y, Guo J, Zheng Y. , et al; BRIGHT Investigators. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA 2015; 313 (13) 1336-1346
21 Valgimigli M, Frigoli E, Leonardi S. , et al; MATRIX Investigators. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med 2015; 373 (11) 997-1009
22 Erlinge D, Omerovic E, Fröbert O. , et al. Bivalirudin versus heparin monotherapy in myocardial infarction. N Engl J Med 2017; 377 (12) 1132-1142